# ArtBlood

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artblood

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.artblood.kr/
- Total disclosed funding: $0.4M
- Latest round: Seed (Aug 30, 2022)
- Investors on record: 3

## About

Founded in 2022 and based in Seoul, South Korea, Art Blood Co., Ltd., operates as a biotechnology company that produces blood for transfusion. In April 2024, ArtBlood raised KRW 6.5 billion in venture funding from Partners Investment, Korea Development Bank, Won & Partners, and Heungkuk Securities. As of 2024, the company is led by its CEO, Baek Eun-jeong.

The company offers a cell-based in vitro blood production system used to produce various blood types, including universal donor blood.

The company’s product pipeline includes products like UniArt Cell Line and DiArt Cell Line used for blood transfusions and differentiating into red blood cells of various types, including the universal O negative type.

## Funding rounds

- Seed, Aug 30, 2022 — Yonsei Technology Holdings, Korea Investment Accelerator
- Seed, Jun 1, 2022, $0.4M — Korea Tech Incubator for Startup, Yonsei Technology Holdings

## Investors

- Korea Tech Incubator for Startup — Seed
- Yonsei Technology Holdings (https://capitalatlas.ai/funds/yonsei-technology-holdings) — Seed
- Korea Investment Accelerator (https://capitalatlas.ai/funds/korea-investment-accelerator) — Seed